Physician profile
Keith V Rundle
NPI 1245267285
$2,685.00
in general payments reported to CMS, 2019-2025
22 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $501 · 2021: $273 · 2022: $526 · 2023: $272 · 2024: $359 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Entertainment: $17.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.71 |
| Entertainment | $17.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $791.00 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Carl Zeiss Meditec, INC. | $397.40 | 2020 | |
| Glaukos Corporation | $240.71 | 2019-2025 | Idosetr, Kxl System (Not Refurbished), Istent Infinite |
| Abbvie INC. | $214.02 | 2022-2025 | Durysta |
| Genentech USA, INC. | $149.04 | 2022 | |
| Aerie Pharmaceuticals, INC. | $128.98 | 2019-2021 | |
| Horizon Therapeutics Plc | $104.43 | 2022-2023 | Tepezza |
| Allergan, INC. | $93.83 | 2021 | |
| Sight Sciences, INC. | $89.23 | 2021-2022 | |
| Astellas Pharma US INC | $64.18 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $60.82 | 2023-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.50 | 2020-2022 | |
| Dutch Ophthalmic, USA | $38.40 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $37.12 | 2022-2023 | Tecnis Iol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $36.50 | 2025 | Xdemvy |
| Harrow Eye, LLC | $35.50 | 2024 | Iheezo |
| Bausch & Lomb Americas INC. | $35.25 | 2022-2024 | Envista Envy |
| Rxsight INC | $21.36 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Optos, INC. | $17.58 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Mallinckrodt Hospital Products INC. | $16.23 | 2022 | |
| Beaver-Visitec International, INC. | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Rundle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.